Tarsus Pharmaceuticals Inc. (TARS) valuation against sector peers: P/B 9.1, free-cash-flow yield 1.8%, P/S 5.2.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	TARS	Sector median	vs median
P/E	—	30.6 · n=152	—
P/B	9.1	4.0 · n=305	128% above
P/S	5.2	4.4 · n=297	18% above
EV/EBIT	—	25.8 · n=139	—
Free-cash-flow yield	1.8%	1.4% · n=287	25% above
Dividend yield	0.00%	0.00% · n=358	—
Return on equity	−13.7%	−3.7% · n=306	—
Return on invested capital	−18.6%	0.4% · n=275	4,354% below
Gross margin	—	61.7% · n=202	—
Net debt / EBITDA	—	1.31 · n=146	—

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Value factor: 45 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	45.4	35.8	—	1.5%	0.6%	7/10
JNJJohnson & Johnson	40.5	8.0	—	3.2%	1.9%	8/10
ABBVAbbVie	80.6	—	33.8	3.6%	3.0%	5/10
UNHUnitedHealth	25.9	3.5	19.1	6.5%	2.2%	9/10
MRKMerck	109.6	8.3	—	4.6%	2.4%	9/10
TMOThermo Fisher Scientific	37.4	4.9	36.7	2.8%	0.3%	10/10
AMGNAmgen	27.9	20.9	25.2	4.2%	2.2%	7/10
GILDGILEAD	—	16.7	—	6.6%	2.0%	5/10
ABTAbbott	28.4	3.4	26.8	4.1%	3.0%	6/10
PFEPfizer	38.7	2.0	—	6.5%	7.3%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 06 Aug 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings